

A1  
--(2) The preparation of the specimen suspension:  
vaginal secretion was taken by a cotton swab from one of the  
patients with vaginal secretions of pH value less than 4.0.  
Then the swab was washed in 2ml sterilized Trypcase-soy Broth  
immediately, and thus the specimen suspension was ready. The  
vaginal secretion smear dyeing showed that there are many Gram-  
positive bacilli, positive cocci and Gram-negative bacilli are  
little.--

In the Claims:

Please cancel Claims 1-18 without prejudice to presentation in a  
divisional application. Please also cancel Claims 19-21 without  
prejudice.

Please add the following new Claims 22-38.

A2  
22. (New) A method of reducing the acidity in the vagina,  
comprising administering vaginally to a subject an effective  
amount of a composition comprising:

one or more substances selected from the group consisting of  
amino acid, physiologically acceptable salt of amino acids,  
oligopeptides, and polypeptides; wherein the said amino acids  
and/or salt of amino acids thereof are selected from the group  
consisting of glutamic acid, glutamine, aspartic acid,  
asparagine, isoleucine, methionine, phenylalanine, tyrosine,

valine, leucine, proline, threonine, cysteine, alanine, glycine, serine, lysine, arginine, tryptophane and histidine; the oligopeptides and polypeptides are the oligopeptides and polypeptides contained in tryptone or other kinds of hydrolysis products of proteins or yeast extracts; and

one or more pharmaceutical carriers.

23. (New) A method according to Claim 22, wherein said method is for treating vaginitis with abnormally high vaginal acidity of a pH value less than 4.0.

24. (New) A method according to Claim 22, where the said method is for treating fungal vaginitis.

25. (New) The method according to Claim 22, wherein the said composition is in the form of viscous gels, lotion, tablets, effervescent tablets, suppositories, emulsion, ointments or micro-capsules.

26. (New) The method according to Claim 22, wherein the said physiologically acceptable salts of amino acids is the sodium salt, potassium salt, calcium salt, magnesium salt of amino acids.

27. (New) The method according to Claim 26, wherein the said physiologically acceptable salt of amino acid is the sodium salt of amino acid.

28. (New) The method according to Claim 22, wherein the total content of amino acids, and the physiologically acceptable salts of amino acids, is in the range of 30-350mmol/L.

29. (New) The method according to Claim 28, wherein the total content of amino acids, and the physiologically acceptable salts of amino acids, is in the range of 80-200mmol/L.

30. (New) The method according to Claim 22, wherein the total content of amino acids, salts of amino acids, oligopeptides, polypeptides is in the range of 0.5-15% (W/V).

31. (New) The method according to Claim 30, wherein the total content of amino acids, salts of amino acids, oligopeptides, polypeptides is in the range of 2.0-6.0% (W/V).

32. (New) The method according to Claim 22, wherein the composition further comprises:

one or more pharmaceutical alkalis selected from the group consisting of calcium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium lactate, sodium citrate, sodium acetate, calcium carbonate, potassium bicarbonate, sodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate.

33. (New) The method according to Claim 22, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole,

Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

34. (New) The method according to Claim 32, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole, Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

35. (New) The method according to Claim 22, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

36. (New) The method according to Claim 32, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

37. (New) The method according to Claim 33, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus

Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

38. (New) The method according to Claim 34, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescens, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

Add B'